PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: bankruptcy

What’s New in the Guidelines

Feb 01, 2022 · Post-Exposure Prophylaxis (PEP): • The Panel recommends against the use of the anti-SARS-CoV-2 mAbs bamlanivimab plus etesevimab and casirivimab plus imdevimab as PEP because they have markedly reduced susceptibility to the B.1.1.529 (Omicron) variant of concern (VOC), which is currently the dominant SARS-CoV-2 variant in the United States.

Tags:

  Guidelines, Post, Exposure, Prophylaxis, Post exposure prophylaxis

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Related search queries